Hims & Hers stock tumbled after the company confirmed it would stop selling some compounded weight-loss drugs.

Hims & Hers Health, Inc. HIMS delivered an earnings per share (EPS) of 11 cents in fourth-quarter 2024, compared with the ...

The FDA has resolved the shortage of Wegovy and Ozempic, but companies like Hims and Hers may halt sales of compounded ...

In this video, I will go over the fourth-quarter earnings report from Hims & Hers (NYSE: HIMS) and explain why the stock crashed on Tuesday. Watch the short video to learn more, consider subscribing, ...

Telehealth provider Hims & Hers said it will tell consumers they need to seek “alternative options on the commercial dosing,” ...

Stocks are pulling back sharply from their premarket gains, after this morning's consumer confidence reading came in at 98.3 for February. This is well below expectations of 102.3 and a 7-point drop, ...